why choose us

First received: April 10, 2023

Clinical Trial: Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Study Status: Completed

Recruit Status: RECRUITING

Condition: Type 2 Diabetes Mellitus in Obese

Study Type: INTERVENTIONAL


Official Title: Pioglitazone, Lipotoxicity, and Heart Failure With Preserved Ejection Fraction (HFpEF)

Brief Summary: Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure.The main question it aims to answer are:To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals.To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by…

Read more